Replimune Group (NASDAQ:REPL) Sees Strong Trading Volume – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL) shares saw unusually-high trading volume on Wednesday . Approximately 2,589,778 shares were traded during mid-day trading, an increase of 73% from the previous session’s volume of 1,494,138 shares.The stock last traded at $6.9770 and had previously closed at $7.01.

Analyst Upgrades and Downgrades

Several analysts recently commented on REPL shares. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $18.00 in a report on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. HC Wainwright upgraded shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, October 27th. Piper Sandler raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a research note on Monday, October 20th. Finally, JPMorgan Chase & Co. raised Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective for the company in a research report on Monday, October 20th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.75.

Replimune Group Stock Down 2.4%

The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. The firm has a market capitalization of $604.77 million, a P/E ratio of -2.23 and a beta of 0.72. The business has a 50 day moving average price of $9.19 and a 200 day moving average price of $7.48.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). On average, analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $11.13, for a total value of $111,300.00. Following the sale, the chief executive officer directly owned 333,576 shares in the company, valued at $3,712,700.88. This trade represents a 2.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Christopher Sarchi sold 5,208 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $9.10, for a total value of $47,392.80. Following the completion of the sale, the insider owned 123,088 shares of the company’s stock, valued at $1,120,100.80. This represents a 4.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 25,625 shares of company stock valued at $257,607. Company insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its position in Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after buying an additional 1,879 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Replimune Group in the second quarter valued at approximately $69,000. Russell Investments Group Ltd. raised its stake in shares of Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after acquiring an additional 7,569 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Replimune Group by 2,020.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock worth $90,000 after acquiring an additional 9,235 shares in the last quarter. Finally, AlphaQuest LLC boosted its holdings in shares of Replimune Group by 99.9% in the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company’s stock worth $92,000 after acquiring an additional 4,925 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.